CJC-1295 without DAC + IpamorelinAlso known as: CJC 1295 no DAC, CJC-1295 without drug affinity complex, Ipamorelin, Growth hormone releasing peptide (GHRP-5)

Mechanism of Action

CJC-1295 without DAC is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates endogenous secretion of growth hormone (GH) via pulsatile release from the anterior pituitary. Ipamorelin is a growth hormone releasing peptide (GHRP) that acts as an agonist of the ghrelin receptor (GHSR-1a), also augmenting GH release. The combination synergistically increases GH secretion without significant desensitization or side effects by activating two separate pathways: GHRH-induced cAMP-mediated GH release and ghrelin receptor mediated GH release.

Reported Research Benefits

Widely used in preclinical research to study growth hormone secretion, muscle regeneration, fat metabolism, sleep quality, and IGF-1 elevation. Investigated for effects on accelerated tissue recovery, adipose tissue reduction, and improved body composition in animal models.

Dosing Protocol & Reconstitution

Typically supplied as lyophilized powder to be reconstituted with bacteriostatic water for subcutaneous injection. Research doses vary but commonly used ranging from 10mg to 20mg batches, with dosing protocols designed to create pulsatile GH release avoiding receptor desensitization. Stability post-reconstitution is up to 60 days refrigerated (2–8°C).

Research Notes

This peptide blend demonstrates a balanced GH release profile with minimal elevation of cortisol or prolactin, exhibiting a mild side effect profile. It is preferred for chronic or repeated dosing studies investigating long-term effects of GH pulsation on tissue repair and metabolic outcomes. Batch purity is verified independently at ≥99%.

Research Summary

Equivalent to the CJC-1295 (No DAC) + Ipamorelin combination. This synergistic GHRH/GHRP stack triggers coordinated pulsatile GH release, closely mimicking physiological patterns. Studies support improvements in lean mass, fat oxidation, bone density, and sleep architecture.

Side Effects & Safety

Mild water retention, headache, and transient fatigue possible. IGF-1 elevation carries standard growth factor precautions. Injection site reactions may occur.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: CJC-1295 without DAC: D-Ala-Glu-His-Trp-Ser-Ala-Asp-Arg-Lys-Val-Leu-Gly-Arg-Arg-Asn-Cys Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+Ipamorelin+growth+hormone+secretagogue